Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kenneth Koury
Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial
The Lancet
Medicine
Related publications
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Gastroenterology
Hepatology
Gastroenterology
Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection
Eastern Mediterranean Health Journal
Medicine
Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response
Hepatology
Medicine
Hepatology
Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1
American Journal of Gastroenterology
Hepatology
Gastroenterology
Renal Dysfunction With Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin Therapy
Acta Hepatologica Japonica
Hepatology
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Gastroenterology
Hepatology
Gastroenterology
Mixed Treatment Comparisons to Compare Simeprevir With Boceprevir and Telaprevir in Combination With Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected With Genotype 1 Hepatitis C Virus (Hcv)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PIN50 the Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis From the Perspective of the Scottish National Health Service (NHS)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naive Patients With Hepatitis C Virus Genotype 2 or 3
Clinical Medicine and Research
Medicine
Home Care
Community
